GENINCODE PLC
Trading as GENinCode, the company describes itself as a predictive genetics business focused on the prevention of cardiovascular disease and the risk assessment of ovarian cancer, combining clinical algorithms with AI-based bioinformatics in its in vitro diagnostic molecular tests. Its product range includes Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode® for cardiovascular genetic risk, alongside the ROCA® ovarian cancer surveillance test added with the acquisition of Abcodia Limited in September 2022. The group states that it operates in the UK, in continental Europe through a Spanish operating subsidiary, and in the United States.
GENINCODE PLC’s ordinary shares have traded on AIM, London Stock Exchange’s market for smaller growing companies, under the ticker GENI since 24 July 2021, when the company raised £17 million gross at 44 pence per share. For the six months to 30 June 2025, the company reported group revenue of £1.60 million, up 15% on the £1.39 million reported for the same period in 2024, alongside an adjusted EBITDA loss of £2.07 million; full-year 2025 revenue guidance was subsequently revised to £3.3 million. In March 2025, GENinCode completed a £3.7 million net fundraising, and the company has reported its first commercial NHS contract, with University College London Hospitals, for ROCA ovarian cancer surveillance testing.
Registration details
Company overview
GENINCODE PLC is a public limited company registered in England and Wales under company number 11556598. It was incorporated on 6 September 2018, initially as GENINCODE UK LIMITED before briefly trading as GENINCODE LIMITED and adopting its current name on 16 July 2021, and is recorded as active on the Companies House register. The company’s registered office is at One, St. Peters Square, Manchester, M2 3DE, and Companies House classifies its principal activity under SIC code 72110, research and experimental development on biotechnology.
Officers
12
Directors and officers of GENINCODE PLC
Companies House records eight active officer appointments for GENINCODE PLC, covering seven individuals, since Paul Andrew Peter Foulger serves as both a Director and Company Secretary, and four resigned directors. The current board comprises Paul Andrew Peter Foulger (Director, appointed 1 April 2021; Company Secretary, appointed 16 July 2021), Jordi Puig Gilberte (Director, appointed 6 September 2018), Matthew Heaton Walls (Director, appointed 6 September 2018), William Edward Rhodes (Director, appointed 1 January 2021), Sergio Olivero (Director, appointed 1 May 2020), Huon Hamilton Gray (Director, appointed 21 February 2022) and Felix Wilhelm Frueh (Director, appointed 1 April 2022). Recorded nationalities are British (Foulger, Walls, Gray), Spanish (Gilberte, Olivero), American (Rhodes) and Swiss/American (Frueh), with countries of residence in England, the United Kingdom, Spain and the United States respectively. This reflects Companies House officer data reviewed 18 September 2026.
Recent officer changes
- Felix Wilhelm Frueh appointed Director, 1 April 2022 (source: Companies House).
- Huon Hamilton Gray appointed Director, 21 February 2022 (source: Companies House).
- David Eric Evans resigned as Director, 26 November 2021, having been appointed 1 May 2020 (source: Companies House).
Data availability
Classification: Full. Companies House publishes current and historical officer appointment and resignation dates together with nationality and country of residence for GENINCODE PLC’s directors; occupation, as distinct from legal role, and residential addresses are not separately reported.
Sources
- Companies House – Officers list, company number 11556598
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of GENINCODE PLC
GENINCODE PLC is the ultimate identifiable UK parent of a small corporate group built around its cardiovascular and oncology genetic-testing business. Companies House’s persons-with-significant-control filings confirm three UK subsidiaries: GENINCODE UK LIMITED (company number 13455587), in which GENINCODE PLC holds 75% or more of shares and voting rights, notified 14 June 2021; Abcodia Limited (07383925), acquired in September 2022 for up to £1 million on an earn-out basis and confirmed via a PSC notification dated 26 September 2022, giving GENINCODE PLC 75% or more of shares and voting rights; and Abcodia CS Ltd (08416006), also 75%-or-more controlled by GENINCODE PLC as of 26 September 2022, having previously been controlled by Abcodia Limited until that date. The company’s own investor materials additionally describe a Spanish operating subsidiary, GENinCode S.L.U., through which the group conducts business in continental Europe, and a US subsidiary, GENinCode U.S. Inc.; ownership percentages for these non-UK entities were not independently confirmed through a UK registry during this research. Group information reviewed 18 September 2026.
Verified corporate relationships
Swipe or scroll for more columns
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| GENINCODE UK LIMITED | GB | 13455587 | Direct subsidiary | 75% or more of shares & voting rights | Active | 14 Jun 2021 (PSC notified) |
| Abcodia Limited | GB | 07383925 | Direct subsidiary | 75% or more of shares & voting rights | Active | 26 Sep 2022 (PSC notified) |
| Abcodia CS Ltd | GB | 08416006 | Indirect subsidiary | 75% or more of shares & voting rights | Active | 26 Sep 2022 (PSC notified) |
| GENinCode S.L.U. | ES | Not independently confirmed | Possible relationship (European operating subsidiary per company materials) | Ownership percentage not disclosed | Active (per company website) | 2026 (company website) |
Recent structural changes
- Acquisition of Abcodia Limited and its subsidiary Abcodia CS Ltd, completed September 2022 for up to £1 million on an earn-out basis, adding the ROCA® ovarian cancer risk test to the group (source: company announcements; Companies House PSC filings).
Data availability
Classification: Partial. GENINCODE PLC’s UK subsidiaries and their ownership percentages are fully verified through Companies House PSC filings; its disclosed Spanish and US operating entities could not be independently confirmed through a UK company registry and are described here on the basis of the company’s own investor materials only.
Sources
- Companies House – Persons with Significant Control register, company numbers 11556598, 13455587, 07383925 and 08416006
- Companies House – Company overview, company numbers 11556598, 13455587, 07383925 and 08416006
- GENinCode plc investor materials, investors.genincode.com
GENINCODE PLC
United Kingdom
Frequently asked questions
What does GENINCODE PLC do?
GENinCode plc (company number 11556598) is a public limited company registered in England and Wales, incorporated 6 September 2018 and registered at One, St. Peters Square, Manchester, M2 3DE; trading as GENinCode, it is a predictive genetics company focused on cardiovascular disease risk assessment and ovarian cancer testing, combining clinical algorithms with AI bioinformatics in its Cardio inCode, Lipid inCode, Thrombo inCode, Sudd inCode and ROCA diagnostic tests.
Who owns GENINCODE PLC?
GENinCode plc has been exempt from Companies House persons-with-significant-control disclosure since 5 September 2021 due to its AIM listing; its active PSC statement, filed 21 July 2021, records no registrable person or entity, and prior individual controllers Matthew Heaton Walls and Jordi Giblerte Puig ceased their significant-control positions in 2020-2021.
Who is GENINCODE PLC's UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) data is recorded for GENINCODE PLC; access to beneficial-ownership data in this jurisdiction is governed by its own register rules.
What is GENINCODE PLC's company registration number?
GENINCODE PLC's registration number is 11556598, filed with Companies House in United Kingdom. Its current status on the register is active.
Is GENINCODE PLC still an active company?
GENINCODE PLC's status on Companies House is listed as active.
When was GENINCODE PLC incorporated?
GENINCODE PLC was incorporated on 6 September 2018, according to Companies House.
What is GENINCODE PLC's registered address?
The registered address on file for GENINCODE PLC is Manchester, United Kingdom.
What legal structure is GENINCODE PLC registered as?
GENINCODE PLC is registered as a Public Limited Company in United Kingdom.
What is GENINCODE PLC's revenue?
GENinCode plc reported group revenue of GBP 1.60 million for the six months ended 30 June 2025, up 15% on GBP 1.39 million in H1 2024, with full-year 2025 revenue guidance subsequently revised to GBP 3.3 million; FY2023 revenue was GBP 2.2 million.
Is GENINCODE PLC listed on a stock exchange?
GENinCode plc ordinary shares have traded on AIM, London Stock Exchange market for smaller growing companies, under the ticker GENI (ISIN GB00BL97B504) since 24 July 2021, when the company raised GBP 17 million gross at 44 pence per share.
Who are the officers/directors of GENINCODE PLC?
Companies House records eight active officer appointments for GENinCode plc, covering seven individuals as of 18 September 2026, including Jordi Puig Gilberte, Matthew Heaton Walls, William Edward Rhodes, Sergio Olivero, Huon Hamilton Gray, Felix Wilhelm Frueh and Paul Andrew Peter Foulger (who serves as both Director and Company Secretary), alongside four resigned directors.
Does GENINCODE PLC have a parent company or subsidiaries?
GENinCode plc directly or indirectly controls three verified UK subsidiaries per Companies House PSC filings – GENINCODE UK LIMITED, Abcodia Limited and Abcodia CS Ltd, the latter two added through the September 2022 acquisition of the ROCA ovarian cancer test – and its investor materials describe additional Spanish and US operating subsidiaries not independently confirmed through a UK registry.
Can Zavia monitor changes to GENINCODE PLC's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to GENINCODE PLC's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access GENINCODE PLC's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like GENINCODE PLC's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 18 September 2026.